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Edited by Robert B. RussellAbstract NF-jB activation plays a crucial role in anti-apoptotic
responses in response to the apoptotic signaling during tumor
necrosis factor (TNF)-a stimulation. TNF-a induces apoptosis
sensitive to the hepatitis B virus (HBV) infected cells, despite sus-
tained NF-jB activation. Our results indicate that the HBV
infection induces sustained NF-jB activation, in a manner similar
to the TNF-a stimulation. However, these eﬀects are not merely
combined. Computational simulations show that the level of form
of the IKK complex activated by phosphorylation (IKK-p) aﬀects
the dynamic pattern of NF-jB activation during TNF-a stimula-
tion in the following ways: (i) the initial level of IKK-p determines
the incremental change in IKK-p at the same level of TNF-a stim-
ulation, (ii) the incremental change in IKK-p determines the
amplitudes of active NF-jB oscillation, and (iii) the steady state
level of IKK-p after the incremental change determines the period
of active NF-jB oscillation. Based on experiments, we observed
that the initial level of IKK-p was upregulated and the active
NF-jB oscillation showed smaller amplitudes for a shorter period
in HepG2.2.15 cells (HBV-producing cells) during TNF-a
stimulation, as was indicated by the computational simulations.
Furthermore, we found that during TNF-a stimulation, NF-jB-
regulated anti-apoptotic genes were upregulated in HepG2 cells
but were downregulated in HepG2.2.15 cells. Based on the previ-
ously mentioned results, we can conclude that the IKK-p-level
changes induced by HBV infection modulate the dynamic pattern
of active NF-jB and thereby could aﬀect NF-jB-regulated anti-
apoptotic gene expressions. Finally, we postulate that the
sensitive apoptotic response of HBV-infected cells to TNF-a
stimulation is governed by the dynamic patterns of active
NF-jB based on IKK-p level changes.
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The hepatitis B virus (HBV), a member of the hepadnavirus
family, has infected 350 million people worldwide [1]. In
5–10% of patients, the infection advances to lifelong chronic
hepatitis B, which is frequently a precursor of cirrhosis and
hepatocellular carcinoma [2]. Generally, in host cells, NF-jB
is activated by pathogenic viruses [3]. HBV also activates
NF-jB in the host cells; this activation is mediated by HBx,
preS2, etc. [4–6]. NF-jB may be involved in oncogenesis.
In a manner similar to HBV, many oncogenes are able to acti-
vate NF-jB, and its activity is required for subsequent
transformation [7,8]. Furthermore, the viral counterpart of
NF-jB–v-Rel is highly oncogenic [9]. Some recent reviews
have indicated the role of NF-jB in oncogenesis with respect
to its function in promoting cell proliferation and transforma-
tion [7,8].
NF-jB is a collective term and refers to a class of dimeric
transcription factors that belong to the Rel family, which in-
cludes RelA (p65), RelB, c-Rel, NF-jB1 (p50), and NF-jB2
(p52) [10]. Traditional NF-jB activation comprises the nuclear
localization of RelA/NF-jB1 via inhibitor jB (IjB)a degrada-
tion [11]. NF-jB activation signals, such as stimulation of tu-
mor necrosis factor (TNF)-a and lipopolysaccharide
stimulation, result in IjB kinase (IKK) activation by phos-
phorylation [12]. This activated IKK complex (IKK-p) phos-
phorylates the IjBa that is bound to RelA/NF-jB1; this
process is primarily mediated by IKKb. The phosphorylated
IjBa is subjected to ubiquitin-mediated degradation. IjBa
degradation enables the nuclear translocation of the transcrip-
tion factor RelA/NF-jB1, and this leads to various gene tran-
scriptions, including IjBa transcription. This traditional
pathway has a negative feedback loop system that comprises
IjBa bound to RelA/NF-jB1, IjBa, and RelA/NF-jB1. An
increasing amount of attention is being focused on this nega-
tive feedback loop because it plays the signiﬁcant role of regu-
lating RelA/NF-jB1. In an alternative NF-jB activation
pathway, the NF-jB-inducing kinase (NIK)-IKKa cascade isblished by Elsevier B.V. All rights reserved.
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precursor of NF-jB2 (p100) [11]. This phosphorylated protein
is further processed to NF-jB2 (p52) via the degradation of its
inhibitory region. Although NIK is not essential for IKK-b-
dependent NF-jB activation, it participates in the overall acti-
vation of NF-jB, including the activation of NF-jB via IKK-a
and IKK-b [13–15].
Recently, various computational models have been pro-
posed and successfully applied in the context of systems biol-
ogy to solve some interesting biological questions that are
otherwise diﬃcult to answer by using conventional biological
approaches alone [16]. For instance, some subcellular systems
have been investigated by using ordinary diﬀerential equations
(ODEs), and their intrinsic dynamical properties such as adap-
tation [17,18], ampliﬁcation [19], ultrasensitivity [19], multista-
bility [20], and hysteresis [20] were revealed by using the
systems biology approach. A recent study on computational
modeling of the negative feedback loop system in the tradi-
tional NF-jB activation pathway showed that the temporal
control of active NF-jB can diﬀerently regulate the corre-
sponding gene expressions [21]. Following this study, the active
NF-jB regulation system has been widely studied to date
[22,23]; however, the computational model of its upstream sig-
naling component has not yet been well studied. Recently, a
few attempts have been made to propose a computational
model of the entire TNF-a-mediated NF-jB signaling system
based on ODEs [24]; however, the dynamic properties of the
upstream signaling systems and their eﬀects on NF-jB
regulation still remain unclear. In this study, we have
developed a computational model of the TNF-a-mediated
NF-jB activation pathway by further extending Hoﬀmann
et al.’s model [21]. We have investigated the dynamical proper-
ties of traditional NF-jB complex (RelA/NF-jB1) activation
in the traditional pathway induced by TNF-a stimulation dur-
ing HBV infection. Computational simulations demonstrate
that not only the initial level of IKK-p but also the quantity
that comprises this level changes due to external stimulation;
these levels play a crucial role in producing the diﬀerent dy-
namic patterns of NF-jB activation in the TNF-a-mediated
NF-jB pathway. By using in vitro experiments, these results
were then further investigated with HBV infection model
systems since HBV induces IKK-p upregulation. The
upregulation of IKK-p results in diﬀerent dynamic patterns
of TNF-a-mediated NF-jB activation compared to those at
a basal level of IKK-p. These dynamic patterns may cause
diﬀerent regulations of the corresponding anti-apoptotic gene
transcriptions; this could then explain the sensitive apoptotic
responses of HBV-infected cells to TNF-a. Finally, we
postulate that the state change of a system that is caused by
an HBV infection changes the initial status of the system,
which may then distinctly regulate the corresponding
anti-apoptotic gene transcriptions even at the same level of
TNF-a stimulation.2. Materials and methods
2.1. Computational modeling and simulations
Based on the law of mass action, we were able to build a computa-
tional model of the NF-jB pathway by using a set of nonlinear ODEs.
We employed power law functions, which, in turn, give rise to nonlin-
ear models of the formd
dt
miðtÞ ¼
X
f2F i
kif
Y
p2Mf
m
gipf
p ðtÞ 
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b2Bi
kib
Y
q2Mb
mhiqbq ðtÞ
for 1 6 i 6 n, where mi(t) describes the temporal concentration of the
ith component, gipf and hiqb are kinetic orders corresponding to the ele-
mentary processes contributing to the production and degradation of
mi, respectively, and kif and kib are the respective rate constants for
these processes.
In order to facilitate the design and analysis of the computational
model, we employed the ‘‘modular approach’’ [25,26]; we decomposed
the entire pathway system into three substructures based on their func-
tion and dynamical properties (see Supplementary material). Each of
these substructures is characterized and modeled by using sequential
binding reactions (TNF-a receptor system; stage 1), a series of enzy-
matic activations (kinase cascade; stage 2), and a complex reaction net-
work forming a negative feedback loop (NF-jB regulation system;
stage 3). Further, based on this computational model, we take into ac-
count the HepG2/HepG2.2.15 models by introducing additional reac-
tion networks comprising constitutive IKK activation (denoted by the
Factor X) , HBV inducible NIK-IKK activation (denoted by the Fac-
tor Y), and NIK inhibition (denoted by the Factor I) by the TNF
receptor-associate factor (TRAF) complex, including TRAFs-and-
NIK-associated protein (TNAP). The kinetic parameters and initial
concentrations of the participant molecules that were used for the com-
putational simulations were sourced from either literature [17,18,21,
27–29] or public databases (http://doqcs.ncbs.res.in) or estimated from
our own experiments by using relevant assumptions (see appendix in
Supplementary material). A complete set of 52 diﬀerential equations
and 84 parameters are summarized in the appendix. Computational
simulations have been performed using a 2.7 GHz Pentium 4 PC,
and the ODE solver (ode15s function) Matlab R14 (MathWorks,
Inc.) was used to solve the diﬀerential equations.
2.2. Cells and transfections
HepG2 cells were obtained from American Type Culture Collection,
and HepG2.2.15 cells were obtained fromHyeseong Cho (Ajou Univer-
sity, Suwon, Korea). The HepG2.2.15 cells are HBV-transfected vari-
ants of HepG2 cells that have the ability to replicate HBV [30]. The
cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (Sigma) sup-
plemented with 10% fetal bovine serum (Life Technologies Inc.).
2.3. TUNEL assays
Either the HepG2 or HepG2.2.15 cells were seeded on poly-L-lysine-
coated coverslips. At 24 h after the seeding, the cells were treated with
TNF-a (40 ng/ml) for 12 h. After the treatment, the cells were ﬁxed
with 4% methanol-free formaldehyde solution in PBS (pH 7.4) for
25 min at 4 C. Next, the apoptotic cells were detected with the Dead-
EndTM Fluorometric TUNEL System (Promega).
2.4. Electrophoretic mobility shift assay (EMSA)
The nuclear extracts (5 lg) that were obtained from either the
HepG2 cells or HepG2.2.15 cells were incubated for 15 min at 20 C
in 10 ll reaction buﬀer containing 10 mM Tris–HCl (pH 7.5), 50
mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol,
and 1 lg of poly(dI–dC) with 1 ll 32P-5 0-end-labeled dsDNA oligonu-
cleotide (104 cpm/reaction). The dsDNA oligonucleotide, which was
used as either the probe or competitor, contained an NF-jB binding
site corresponding to the sequence 5 0-AGTTGAGGGGACTTTCC-
CAGGC-3 0(Promega). The resolved DNA–protein complexes were
analyzed by electrophoresis through 5% PAGE containing 50 mM
Tris–HCl (pH 8.5), 200 mM glycine, and 1 mM EDTA. The gels were
dried and autoradiographed. When performing the assays with an
unlabeled competitor, a 100-fold molar excess of unlabeled dsDNA
NF-jB oligonucleotide was added simultaneously with the labeled
probe. In the case of the antibody-blocking experiment, anti-p50
(NF-jB1) rabbit polyclonal antibody (Santa Cruz Biotechnology)
was added to the reacting mixture, and the mixture was incubated
for 16 h at 4 C. Next, the abovementioned labeled dsDNA oligonu-
cleotide was added.
2.5. Reverse transcription-polymerase chain reaction analysis
The HepG2 and HepG2.2.15 cells were treated with TNF-a (40 ng/
ml). At the indicated time after treatment, total RNA was extracted
with TRIzol Reagent (Life Technologies), as described in the manufac-
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(RT). Following RT, the synthesized cDNA was ampliﬁed with 2.5 U
Taq Polymerase (Qbio), a glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)-speciﬁc primer set, and an appropriate primer set. The se-
quences of the primer set were as follows: BCL-xL-speciﬁc, Bﬂ-1-spe-
ciﬁc, FLICE inhibitor protein (FLIP)-speciﬁc, growth arrest- and
DNA-damage-inducible proteins 45b (Gadd45b)-speciﬁc, X-chromo-
some-linked inhibitor of apoptosis (XIAP)-speciﬁc, and GAPDH-spe-
ciﬁc. A polymerase chain reaction (PCR) was performed by using a
Gene Amp PCR system 2400 (Perkin–Elmer) with 5 min initial dena-
turation at 95 C and 20–30 cycles of 50 s at 95 C, 50 s at 60 C,
and 50 s at 72 C; these cycles were followed by 7 min of extension
at 72 C. To separate the PCR fragment, 1% agarose gel was used.3. Results
3.1. HepG2.2.15 cells have a more sensitive response to TNF-a
with regard to apoptosis
A previous study demonstrated that TNF-a kills HBx-
expressing cells with more sensitivity than it does control cells
[31]. Moreover, the hepatocytes of an HBV-infected liver have
a faster turnover rate than those of a healthy liver [32]. This
could be due to the death of the HBV-infected hepatocytes
as a result of immune responses [32]. In this study, the sensitiv-
ity of TNF-a-induced apoptosis was tested on HepG2 and
HepG2.2.15 cells by using TUNEL assays that detect the
DNA fragmentation that is induced by apoptotic events. The
results of the analysis reveal that with regard to apoptosis,
the HepG2.2.15 cells responded to TNF-a more sensitively
than HepG2 cells (Fig. 1).
3.2. Computational model of the TNF-a-mediated NF-jB
pathway during HBV infection
It has been reported that both HBV and TNF-a activate
NF-jB, and this activation generally prevents apoptosis. On
the other hand, it has also been observed that TNF-a induces
the apoptosis of HepG2.2.15 cells more sensitively. Based on
previous reports, we can infer that the TNF-a-mediated NF-
jB activation may be aﬀected by HBV infection. In order to
investigate this mechanism in great detail in our study, we em-
ployed computational modeling and simulation as well as
in vitro experiments. Prior to the development of the computa-Fig. 1. TNF-a induces apoptosis more preferentially in HepG2.2.15 cells as c
1· PBS as the control. DNA fragmentations were then analyzed by using TU
stained with 4 0,6-diamidino-2-phenylindole (DAPI).tional model, a schematic diagram (so-called, a ‘‘biological
cartoon’’) of the NF-jB pathway was drawn using data from
a previously reported review article [11]; this diagram had a
slight modiﬁcation based on recently published data [15,33]
(Fig. 2). Recent data revealed that NIK participates in the tra-
ditional and alternative NF-jB pathways via complex forma-
tions with diﬀerent adaptor proteins [15]. Moreover, it was
discovered that TNAP inhibits NIK in the TNF-a-mediated
NF-jB activation [33]. Further, previous reports [4,34] indicate
that HBV activates NF-jB via NIK-dependent pathways. In
this model, we did not consider the alternative NF-jB activa-
tion pathway since it is not activated by TNF-a.
3.3. Dynamic patterns of NF-jB activation depend on the initial
level of IKK-p and the amount of its level change by external
stimulation
The computational simulations demonstrated that the same
level of IKK-p can lead to diﬀerent NF-jB activation dynam-
ics. Moreover, even a smaller level of IKK-p often results in a
higher level of NF-jB activation. These observations moti-
vated us to further investigate the underlying causal relation-
ship in greater detail. In order to investigate whether
diﬀerent initial levels of IKK-p aﬀect the dynamic patterns
of NF-jB activation by upstream signals, the dynamic patterns
of NF-jB activation were analyzed by using computational
simulations with various levels of upstream signal input and
various initial levels of IKK-p. The computational simulation
of TRAFs complex-IKKK-IKK cascade indicates that in re-
sponse to the same level of activated TRAFs complex,
DIKK-p (the amount of IKK-p level change) is larger for a
lower IKK-p(I) (initial level of IKK-p) as compared to that
for a higher IKK-p(I) (Fig. 3B). In our computational model,
DIKK-p is restricted by the total amount of IKK. In the com-
putational simulations of NF-jB (Fig. 3D, E, and F), signals
are introduced in the form of upregulating the IKK-p level
after the initialization for 4000 min. Based on the computa-
tional simulations, we discovered that the amplitude of active
NF-jB (An) after the introduction of the signal has a positive
correlation with DIKK-p. As seen in Fig. 3E, the amplitude
2A1 is almost the same as 1A1 since the DIKK-p of line 1 is
equal to that of line 2. On the other hand, Fig. 3D shows thatompared to HepG2 cells. Cells were treated with TNF-a (40 ng/ml) or
NEL assay, as described in Section 2. In this experiment, nuclei were
Fig. 2. A schematic diagram of the NF-jB activation pathway.
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that of line 1 or line 3. We noted that 2A1 is larger (or not
smaller) than 1A1 even though IKK-p(I) and IKK-p(E) (equi-
librium level of IKK-p) of line 1 are larger than those of line 2,
as seen in Fig. 3D and E. These observations suggest that after
the signal onset, DIKK-p is more important than IKK-p(E) in
determining the amplitude of active NF-jB. Similarly, we
know that IKK-p(E) determines the period (Pn) of active
NF-jB oscillation since 1P1 is almost identical to 2P1 when
lines 1 and 2 have the same IKK-p(E) (Fig. 3F), and on com-
paring 1P1 with 2P1 (Fig. 3D and E), NF-jB activity was ob-
served to exhibit a shorter period corresponding to higher
IKK-p(E). We therefore postulate that the dynamic patterns
of NF-jB activation depend not only on IKK-p(E) but pri-
marily on IKK-p(I) and DIKK-p.
3.4. Levels of activated NF-jB and IKK-p in HepG2.2.15 cells
are higher than those in HepG2 cells before TNF-a signaling
In this study, HepG2.2.15 cells (HBV producing cell line)
were used to investigate the NF-jB activation induced by
HBV, while HepG2 cells were used as a control. The level of
IKK-p in HepG2.2.15 cells is higher than that in HepG2 cells,
as seen in Fig. 4A. This may result in constitutive activation of
NF-jB in the HBV-infected cells. In order to estimate the NF-
jB activity in HepG2.2.15 and HepG2 cells, EMSA was per-
formed with their nuclear extracts. Fig. 4B, C, and D shows
that the NF-jB complexes were activated in both – HepG2
and HepG2.2.15 cells, but the activation in HepG2.2.15 cells
was higher than that in the HepG2 cells; this could have been
caused by HBV. The shifted bands were eﬃciently decreasedby p50 antibody; this represents that the band is the NF-jB/
NF-jB probe complex (Fig. 4C and D).
3.5. IKK-p governs the dynamic patterns of NF-jB activation in
computational simulations of the NF-jB pathway for HBV
infection in response to TNF-a
In order to build a computational model of the NF-jB path-
way during HBV infection, HepG2 and HepG2.2.15 cells are
studied. From these cell lines, the initial concentrations of
some proteins (TRAF2, NIK, IKKa, and IKKb) in the NF-
jB pathway were estimated by immunoblot analysis with stan-
dard proteins. The results revealed that the HepG2.2.15 cells
had a more active (approximately 2.5-fold on an average) form
of NF-jB than the HepG2 cells, as can be seen in Fig. 4. In
addition, this 2.5-fold ratio was not severely changed by the
sampling time if the time was at least 12 h after the seeding.
This implies that the diﬀerence level of active NF-jB at equi-
librium is constant.
Based on the above experimental observations of HepG2
and HepG2.2.15 cells, a computational model is built by
extending the previous NF-jB signaling pathway model. The
extended computational model includes Factor X, Factor Y,
and three stages of the NF-jB pathway, as described in Section
2. To reﬂect sustained NF-jB activation in HepG2 cells, which
is primarily independent of NIK [4,34] (see Supplementary
material), Factor X was introduced in the form of an IKK acti-
vating factor. In addition, Factor Y was introduced in the
form of an NIK activating factor to address the NF-jB activa-
tion induced by HBV, which primarily depends on NIK (see
Supplementary material).
Based on a step change of TNF-a stimulation after initial-
ization from 0 to 0.1 lM, the computational simulation
shows that DIKK-p in HepG2 cells is higher than that in
HepG2.2.15 cells (Fig. 5). This is due to the level of IKK-
p(I) in HepG2 being diﬀerent as compared with that in
HepG2.2.15. On the other hand, the IKK-p(E) in HepG2 is
smaller than that in HepG2.2.15 (Fig. 5). These diﬀerences
(i.e., DIKK-p and IKK-p(E)) are responsible for the oscilla-
tory pattern of active NF-jB with prominently higher ampli-
tudes; further, a longer period of activity is observed in
HepG2 cells after TNF-a treatment as compared with that
in HepG2.2.15 cells.3.6. Dynamic patterns of the active NF-jB complex in HepG2
cells diﬀer from those in HepG2.2.15 cells during TNF-a
stimulation
To analyze the NF-jB activation pattern during TNF-a sig-
naling, the NF-jB activities were estimated by EMSA. EMSA
was performed by using NF-jB probes with nuclear extracts
obtained from HepG2 and HepG2.2.15 cells at the indicated
time immediately after TNF-a treatment, as shown in Fig. 6.
On analysis, we found that in response to TNF-a treatment,
the active NF-jB complex in HepG2.2.15 cells exhibits oscilla-
tion for a shorter period and of smaller amplitudes as com-
pared to the damped oscillatory pattern of HepG2 cells. This
result is presumably due to the diﬀerences between the HepG2
and HepG2.2.15 cells with regard to the levels of DIKK-p and
IKK-p(E). Moreover, the diﬀerences between the HepG2 and
HepG2.2.15 cells with regard to the levels of IKK-p(I) may af-
fect the DIKK-p and IKK-p(E), as shown in the Fig. 3B. How-
ever, we observed a discrepancy in the experimental data
Fig. 3. DIKK-p and IKK-p(E) after input signal determine the amplitude (An) and period (Pn) of active NF-jB oscillation. (A) Deﬁnitions of
notations are indicated. IKK-p(I), initial level of IKK-p before a stimulation; DIKK-p, level of decrement or increment of IKK-p after a stimulation;
IKK-p(E), equilibrium level of IKK-p after a stimulation. (C) A schematic diagram of the NF-jB activation pathway model used for computational
simulations. A computational model of the two-step kinase cascade was constructed, and DIKK-p was monitored after a uniform level of input signal
at 10 diﬀerent levels of IKK-p(I). Based on stage 3 of the computational model, the eﬀects of DIKK-p and IKK-p(E) on An and Pn were analyzed.
Left panel, IKK-p(I), DIKK-p, and IKK-p(E); right panel, dynamic patterns of NF-jB activation. (D) DIKK-p varies at the same level of IKK-p(I).
(E) IKK-p(I) varies at the same level of DIKK-p. (F) D IKK-p is adjusted to the same level of IKK-p(E). In ﬁgures (D, E, and F), line colors in IKKp
correspond to line colors in NF-jBn, active NF-jB complex in the nucleus.
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Fig. 4. Levels of IKK-p and activated NF-jB in HepG2.2.15 cells were increased as compared to their levels in HepG2 cells. (A) Total extracts from
HepG2 and HepG2.2.15 cells were prepared with RIPA lysis buﬀer, and levels of IKK-p were estimated by immunoblot analysis with a IKK-p-
speciﬁc antibody. In this experiment, b-actins were used for the internal control. (B, C, and D) Nuclear extracts were prepared as described in Section
2, and the activated forms of NF-jB were estimated by EMSA with NF-jB labeled with 32P. Shifted NF-jB/NF-jB probe complexes were conﬁrmed
by antibody-mediated blocking experiments using anti-p50 antibodies (Ab), as described in Section 2.
Fig. 5. Computational simulations of TNF-a-mediated NF-jB activation with/without HBV infection. (A) A schematic diagram of the NF-jB
activation pathway model used for computational simulations. (B) Dynamic patterns of active IKK and active NF-jB have been indicated. The
computational simulations were initialized for 4000–6000 min and TNF-a signal was introduced at the zero time point. NF-jBn, active NF-jB
complex in the nucleus and IKK-p, active IKK.
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tional simulation during an initial period; the experimental
data shows a decrease in the active NF-jB complex (i.e.,
undershoot) immediately after TNF-a treatment (Fig. 6).
3.7. The undershoot phenomenon in HepG2.2.15 cells during
TNF-a treatment may arise due to the inhibition of NF-jB
activation induced by HBV
To explicate the undershoot phenomenon observed through-
out the computational simulations, the computational model
of the NF-jB pathway was further revised based on the fact
that TNAP inhibits NIK-mediated NF-jB activation during
TNF-a signaling [33]. Based on this revised model ofHepG2.2.15 cells, a new computational simulation demon-
strates that the level of IKK-p is immediately reduced after
the introduction of a TNF-a signal (Fig. 7). As a result, the ob-
served undershoot of active NF-jB that is speciﬁc to
HepG2.2.15 cells is revealed in the computational simulation
for HepG2.2.15, while the simulation result for HepG2 is un-
changed (Fig. 7). The computational simulation further shows
that the decrement in IKK-p (i.e., the downward DIKK-p) af-
fects the amplitude of NF-jB activation, even if the eﬀect is
not as dominant as compared to the eﬀect of upward DIKK-
p (see Supplementary material). As observed in the simulation
in Fig. 7, DIKK-p in HepG2.2.15 cells is smaller than that in
HepG2 cells, while IKK-p(E) in HepG2.2.15 cells is higher
Fig. 6. The dynamic pattern of active NF-jB complexes in HepG2 cells treated with TNF-a diﬀers from that in HepG2.2.15 cells. Nuclear extracts
were prepared as described in Section 2 at each instance of sampling HepG2 (A and C) and HepG2.2.15 cells (B and D). EMSA was performed with a
NF-jB probe labeled with 32P. The intensities were analyzed with the 1D Image Analysis software (Kodak Digital Science), and the relative
intensities of the active NF-jB complexes with respect to those of HepG2 cells were calculated (C and D). NF-jBn, active NF-jB complex in the
nucleus.
Fig. 7. Computational simulation of a model that is updated with regard to the undershoot phenomenon. The inhibition of NIK by the TRAFs
complex was introduced such that it competed with downstream molecules such as IKK. (A) A schematic diagram of the revised model used for
computational simulations. (B) Dynamic patterns of active IKK and active NF-jB have been indicated. The computational simulations were
initialized for 4000–6000 min, and TNF-a signal was introduced at the zero time point. NF-jBn, active NF-jB complex in the nucleus and IKK-p,
active IKK.
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patterns that are observed in Fig. 5 are still preserved, except
for the undershoot.
3.8. Analysis of anti-apoptotic gene expressions in HepG2 and
HepG2.2.15 cells reveals that the gene expressions diﬀer in
response to TNF-a stimulation
Liver regeneration followed by apoptosis is an important
mediator of chronic liver disease caused by HBV infection
[32]. Previous reports also indicate that an overexpression ofthe HBx protein sensitizes the cell to apoptosis [31]. Our exper-
iment also showed that with regard to apoptosis, HepG2.2.15
cells were more sensitive to TNF-a stimulation than HepG2
cells (see Supplementary material). TNF-a activates two oppo-
site pathways: the anti-apoptotic pathway and the apoptotic
pathway [35]. It is well known that the NF-jB activation inhib-
its apoptosis via the upregulation of anti-apoptotic proteins
such as BCL-xL (preserves mitochondrial integrity), Bﬂ-1
(inhibits the release of cytochrome c and caspase-3 activation),
FLIP (interferes with death receptor signaling), Gadd45b
Fig. 8. Analysis of anti-apoptotic gene expressions in HepG2 and HepG2.2.15 cells after TNF-a treatment. After TNF-a treatment, the total RNA
was extracted from these cells. With the extracted RNA, RT-PCRs were performed with primers speciﬁc to BCL-xL, Bﬂ-1, FLIP, Gadd45b, and
XIAP. In this analysis, GAPDH was coampliﬁed as the internal control. Ampliﬁed products were separated on 1.2% agarose gels, and the band
intensities were analyzed by using the 1D Image Analysis software (Kodak Digital Science); the relative intensities in HepG2.2.15 cells with respect to
each zero time point were calculated. Note that the number of ampliﬁcation cycles was adjusted to avoid saturation.
S.G. Park et al. / FEBS Letters 580 (2006) 822–830 829(downregulates pro-apoptotic JNK signaling), and XIAP
(inhibits caspase-3, -7, and -9) [35,36]. In order to explore
the relationship between diﬀerent oscillatory patterns of NF-
jB activation and anti-apoptotic gene expressions, we com-
pared the mRNA expression levels in HepG2 and HepG2.2.15
cells after TNF-a treatment. Fig. 8 shows that TNF-a acti-
vated most of the anti-apoptotic genes in HepG2 cells, while
it did not activate most of the anti-apoptotic genes in
HepG2.2.15 cells. This indicates that with the same amount
of TNF-a treatment, the overall transcriptions of the anti-
apoptotic genes chosen in this experiment were mostly upreg-
ulated in HepG2 cells but mostly downregulated in
HepG2.2.15 cells.4. Discussion
The dynamical properties of molecular biological systems
are diﬃcult to uncover by means of conventional molecular
biology methods alone. A systems biology approach, on the
other hand, enables us to generate/verify hypotheses concern-
ing the hidden dynamical properties via interdisciplinary
studies [37]. From this point of view, a systems biology ap-
proach has been introduced in this paper in order to investi-
gate the dynamical property underlying the sensitive
apoptosis of HBV-infected cells on TNF-a stimulation. It
has been known that TNF-a induces both – an anti-apoptotic
response via NF-jB activation as well as an apoptotic re-
sponse via caspase activation. These two counteractive re-
sponses with respect to the TNF-a stimulation are normally
balanced but can be prominently inclined to an apoptotic re-
sponse during HBV infection. Also it has been known that
HBV also induces both anti-apoptotic and apoptotic re-
sponses [38]. Under HBV infection, NF-jB activation result-
ing in upregulations of anti-apoptotic genes may compensate
the apoptotic responses. The present study has shown that
the HBV infection induces sustained NF-jB activation in a
manner similar to the TNF-a stimulation, but these eﬀectsare not merely added up. Throughout the computational sim-
ulations, we postulated that the previously mentioned balance
can be disrupted due to diﬀerent dynamics of NF-jB activa-
tion that are caused by not only the initial level of IKK-p but
also the quantity that comprises its level change. The dynam-
ics of TNF-a-mediated NF-jB activation under HBV infec-
tion may result in the reinforcement of the apoptotic
responses. It was reported that the mathematical model for
CD95-mediated apoptosis pathway [39] and this model can
be applied to the TNF-a-mediated apoptosis under HBV
infection in our future study.
Using the HBV infection model system, these results have
been further veriﬁed by experimental data on the dynamic pat-
terns of NF-jB activation and on the expressions of corre-
sponding anti-apoptotic genes. Recently, it was reported that
temporal controls of IKK activity by diﬀerent stimulations
are important for NF-jB activation pattern [40]. The report
focused on responses for diﬀerent stimulation. In this report,
however, we focused on responses for the same stimuli at dif-
ferent initial states.
In our data, oscillatory pattern of NF-jB obtained from
computational simulation nearly matched the pattern ob-
tained from experimental data. Although this is successful
data, points for improving our model are present. In our
present model, the frequencies of the oscillations in computa-
tional simulation seem to be diﬀerent from the frequency in
the experimental results. In computational simulation, gener-
ally, the dependencies of all results on the parameter values
are a critical point. In addition, many factors, which need
to be considered in this model, still remain because biological
systems are more complicated than the model presented in
our report. It can be inferred that increasing biological data
help to make a more precise computational model.
In this report, we found that the initial state of IKK is very
important for NF-jB activation dynamics. These results may
explain the TNF-a-sensitive apoptosis of HBV-infected cells
and demonstrate the beneﬁts of the systems biological ap-
proach in unraveling the hidden dynamics.
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